Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT05482451
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Please Select, Taiwan
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT05438875
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳Department of Hematology, Beijing Hospital, Beijing, China
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
- Conditions
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Stephen Bagley, MD, MSCE
- Target Recruit Count
- 55
- Registration Number
- NCT05345002
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Target Recruit Count
- 30
- Registration Number
- NCT05297123
- Locations
- 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-03-16
- Target Recruit Count
- 20
- Registration Number
- NCT05281965
- Locations
- 🇨🇳
Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Miao pu, Hangzhou, China
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2022-01-03
- Target Recruit Count
- 180
- Registration Number
- NCT05175508
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
- Target Recruit Count
- 160
- Registration Number
- NCT05016349
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Dwight Owen
- Target Recruit Count
- 18
- Registration Number
- NCT04919369
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-04-15
- Target Recruit Count
- 89
- Registration Number
- NCT04793919
- Locations
- 🇵🇹
Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E., Porto, Portugal
🇮🇹AOU Policlinico Dipartimento di Pediatria, Bari, Italy
🇮🇹Ospedale Papa Giovanni XXIII - USS Oncoematologia Pediatrica, Bergamo, Italy
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 1
- Registration Number
- NCT04700176
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.